Centre National De La Recherche Scientifique

Universitè De Montpellier

Adamed Sp. Z O.o.

Instytut Farmakologii Polskiej Akademii Nauk

Uniwersyter Jagiellonski

Anna Wesolowska

Maciej Pawlowski

Jean Martinez

Adam Bucki

Gilles Subra

Monika Marcinkowska

Marcin Kolaczkowski

Andrzej J Bojarski

Grzegorz Satala

Piotr Kowalski

Jolanta Jaśkowska

Katarzyna Mitka

Pawel Zajdel

Anna Partyka

Piotr Popik

Tomasz Kos

Evelina Colacino

Xavier Bantreil

Katarzyna Grychowska

This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, Parkinson's disease, Huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, Irritable Bowel Syndrome. The compounds have the general formula (XIV), wherein the symbols have the meanings given in the description.

[object Object]

Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system. 

Arylosulfonamides for the treatment of CNS diseases

Growing community of inventors

Kraków, Poland

Anna Wesolowska